Omikron-vaccin.
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a clinical study to evaluate the safety, tolerability and...
investors.pfizer.com